Table 1.
Groups | Vaccine | Delivery vector | Plasmid content | Dose * | Route ** |
---|---|---|---|---|---|
A | Lipofectin/ pEGFP-C1-HA2-AS |
Lipofectin, 100 μL |
50 μg | 200 μL | i.d. 50 μL/swell |
B | Phage 54/ pEGFP-C1-HA2-AS |
Phage 54, 1.36×1012 pfu |
1 μg | 200 μL | i.d. 50 μL/swell |
C | Phage 74/ pEGFP-C1-HA2-AS |
Phage 74, 1.38×1012 pfu |
1 μg | 200 μL | i.d. 50 μL/swell |
D | T7-WT/ pEGFP-C1-HA2-AS |
T7-WT, 1.49×1012 pfu |
1 μg | 200 μL | i.d. 50 μL/swell |
E | PBS | PBS | 0 μg | 200 μL | i.d. 50 μL/swell |
* All vaccines were adjusted to 200 μL per dose. Vaccine delivered by Lipofectin contained 50 μg pEGFP-C1-HA2-AS plasmid, while vaccines delivered by phage particles contained 1 μg pEGFP-C1-HA2-AS plasmid.
** i.d. stands for intradermal injection, and multipoint injection was conducted with 50 μL/swell.